EISAI INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-08-21
Last Posted Date
2015-11-03
Lead Sponsor
Eisai Inc.
Target Recruit Count
60
Registration Number
NCT02222324

To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures

Phase 4
Withdrawn
Conditions
Interventions
First Posted Date
2014-08-20
Last Posted Date
2015-02-10
Lead Sponsor
Eisai Inc.
Registration Number
NCT02220972

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

First Posted Date
2014-08-07
Last Posted Date
2016-03-16
Lead Sponsor
Eisai Inc.
Registration Number
NCT02211222

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-08-04
Last Posted Date
2015-11-03
Lead Sponsor
Eisai Inc.
Target Recruit Count
32
Registration Number
NCT02207790

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-06-24
Last Posted Date
2019-01-15
Lead Sponsor
Eisai Inc.
Target Recruit Count
23
Registration Number
NCT02171260
Locations
🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 15 locations
© Copyright 2024. All Rights Reserved by MedPath